Central Nervous System Diseases  >>  MK0249  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK0249 / Merck (MSD)
NCT00420420: MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

Completed
2
144
US
MK0249, Comparator: Placebo (unspecified)
Merck Sharp & Dohme LLC
Alzheimer's Disease
08/08
08/08

Download Options